For example, KRAS mutation testing was not routinely performed in one case diagnosed in 2009, which was early in the era of mutation testing for pancreatic cancer, and not all patients were tested using the DNA- and/or RNA-based gene fusion panels. This evidence concerns the gene KRAS and familial pancreatic carcinoma.